Irene Modesto

1.8k total citations
66 papers, 1.2k citations indexed

About

Irene Modesto is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Irene Modesto has authored 66 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Genetics, 36 papers in Epidemiology and 21 papers in Surgery. Recurrent topics in Irene Modesto's work include Inflammatory Bowel Disease (56 papers), Microscopic Colitis (34 papers) and Biosimilars and Bioanalytical Methods (10 papers). Irene Modesto is often cited by papers focused on Inflammatory Bowel Disease (56 papers), Microscopic Colitis (34 papers) and Biosimilars and Bioanalytical Methods (10 papers). Irene Modesto collaborates with scholars based in United States, Italy and United Kingdom. Irene Modesto's co-authors include Mario Cottone, Chinyu Su, Ambrogio Orlando, William J. Sandborn, Silvio Danese, Nervin Lawendy, Julián Panés, Bruce E. Sands, Filippo Mocciaro and Valeria Criscuoli and has published in prestigious journals such as Gastroenterology, Gut and Annals of the Rheumatic Diseases.

In The Last Decade

Irene Modesto

63 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Irene Modesto United States	20	834	584	313	186	156	66	1.2k
Antonio López–Sanromán Spain	21	778 0.9×	624 1.1×	369 1.2×	104 0.6×	69 0.4×	68	1.2k
Helena Tavares de Sousa Portugal	13	904 1.1×	658 1.1×	320 1.0×	61 0.3×	106 0.7×	39	1.2k
Véred Abitbol France	24	876 1.1×	727 1.2×	413 1.3×	97 0.5×	176 1.1×	66	1.7k
Yago González‐Lama Spain	19	989 1.2×	798 1.4×	402 1.3×	71 0.4×	66 0.4×	51	1.4k
Adrian Goldiș Romania	12	464 0.6×	358 0.6×	191 0.6×	104 0.6×	116 0.7×	35	770
Yamile Zabana Spain	20	617 0.7×	564 1.0×	303 1.0×	93 0.5×	72 0.5×	85	1.1k
D. H. Present United States	6	1.4k 1.7×	1.1k 1.9×	505 1.6×	114 0.6×	80 0.5×	11	1.7k
Chadwick Williams Canada	12	937 1.1×	694 1.2×	502 1.6×	65 0.3×	120 0.8×	20	1.4k
Iván Guerra Spain	20	470 0.6×	281 0.5×	364 1.2×	66 0.4×	144 0.9×	73	1.0k
Lieven Pouillon Belgium	20	758 0.9×	578 1.0×	261 0.8×	57 0.3×	170 1.1×	51	1.2k

Countries citing papers authored by Irene Modesto

Since Specialization

Citations

This map shows the geographic impact of Irene Modesto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irene Modesto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irene Modesto more than expected).

Fields of papers citing papers by Irene Modesto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Irene Modesto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irene Modesto. The network helps show where Irene Modesto may publish in the future.

Co-authorship network of co-authors of Irene Modesto

This figure shows the co-authorship network connecting the top 25 collaborators of Irene Modesto. A scholar is included among the top collaborators of Irene Modesto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Irene Modesto. Irene Modesto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Peyrin‐Biroulet, Laurent, Marla C. Dubinsky, Bruce E. Sands, et al.. (2024). Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme. Journal of Crohn s and Colitis. 18(8). 1270–1282. 16 indexed citations

Regueiro, Miguel, Britta Siegmund, Andrés Yarur, et al.. (2024). Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events from the ELEVATE UC Clinical Programme. Journal of Crohn s and Colitis. 18(10). 1596–1605. 6 indexed citations

Lees, Charlie W., Joana Torres, Yvette Leung, et al.. (2024). P540 Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: An analysis of the phase 2 OASIS and phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials. Journal of Crohn s and Colitis. 18(Supplement_1). i1055–i1057.

Peyrin‐Biroulet, Laurent, Marla C. Dubinsky, B E Sands, et al.. (2023). P407 Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials. Journal of Crohn s and Colitis. 17(Supplement_1). i536–i538. 4 indexed citations

Lichtenstein, Gary R., Benjamin L. Cohen, Leonardo Salese, et al.. (2023). Impact of Concomitant Corticosteroids on Tofacitinib Induction Efficacy and Infection Rates in Ulcerative Colitis. Digestive Diseases and Sciences. 68(6). 2624–2634. 1 indexed citations

Chiorean, Michael, Marco Daperno, Charlie W. Lees, et al.. (2023). Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program. Advances in Therapy. 40(10). 4440–4459. 1 indexed citations

Vermeire, Séverine, Andrés Yarur, David T. Rubin, et al.. (2023). P476 Characterization of cardiac conduction abnormalities reported in the phase 3 ELEVATE programme. Journal of Crohn s and Colitis. 17(Supplement_1). i604–i606. 3 indexed citations

D’Haens, Geert, Marla C. Dubinsky, Laurent Peyrin‐Biroulet, et al.. (2023). P632 Etrasimod induction therapy in moderately to severely active Crohn’s disease: results from a phase 2, randomised, double-blind substudy. Journal of Crohn s and Colitis. 17(Supplement_1). i764–i765. 14 indexed citations

Rubin, David T., Joana Torres, Iris Dotan, et al.. (2023). An Insight into Patients’ Perspectives of Ulcerative Colitis Flares via Analysis of Online Public Forum Posts. Inflammatory Bowel Diseases. 30(10). 1748–1758. 4 indexed citations

10.

Schreiber, Stefan, David T. Rubin, Siew C. Ng, et al.. (2023). Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme. Journal of Crohn s and Colitis. 17(11). 1761–1770. 17 indexed citations

11.

Vermeire, Séverine, David T. Rubin, Laurent Peyrin‐Biroulet, et al.. (2023). S905 Impact of Etrasimod on Blood Pressure and Hypertension: Data From the Etrasimod Ulcerative Colitis Clinical Program. The American Journal of Gastroenterology. 118(10S). S675–S675.

12.

Rubin, David T., Julián Panés, Joana Torres, et al.. (2023). P781 Treatment outcome of tofacitinib dose reduction to 5 mg BID vs remaining on 10 mg BID in patients with Ulcerative Colitis who were in stable remission on 10 mg BID: Updated 30-month data from the double-blind, randomised RIVETING study. Journal of Crohn s and Colitis. 17(Supplement_1). i914–i916. 1 indexed citations

13.

Kristensen, Lars Erik, Silvio Danese, Cunshan Wang, et al.. (2023). Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Annals of the Rheumatic Diseases. 82(7). 901–910. 72 indexed citations

14.

Dignaß, Axel, et al.. (2021). Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany. Journal of Medical Economics. 24(1). 279–290. 10 indexed citations

15.

Panés, Julián, Séverine Vermeire, Marla C. Dubinsky, et al.. (2021). Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials. Journal of Crohn s and Colitis. 15(11). 1852–1863. 20 indexed citations

16.

Gottlieb, Klaus, Marco Daperno, Keith Usiskin, et al.. (2020). Endoscopy and central reading in inflammatory bowel disease clinical trials: achievements, challenges and future developments. Gut. 70(2). 418–426. 44 indexed citations

17.

Dignaß, Axel, John Waller, Joseph C. Cappelleri, et al.. (2019). Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs. Journal of Medical Economics. 23(4). 415–427. 12 indexed citations

18.

Criscuoli, Valeria, Irene Modesto, Ambrogio Orlando, & Mario Cottone. (2013). Mesalazine for the treatment of inflammatory bowel disease. Expert Opinion on Pharmacotherapy. 14(12). 1669–1678. 33 indexed citations

19.

Renna, Sara, Calogero Cammà, Irene Modesto, et al.. (2008). Meta-Analysis of the Placebo Rates of Clinical Relapse and Severe Endoscopic Recurrence in Postoperative Crohn's Disease. Gastroenterology. 135(5). 1500–1509. 66 indexed citations

20.

Cottone, Mario, Maria Concetta Renda, L Oliva, et al.. (2006). Incidence of Crohn’s disease and CARD15 mutation in a small township in Sicily. European Journal of Epidemiology. 21(12). 887–892. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact